Drug General Information (ID: DDIRWI439U)
Drug Name			Tranexamic acid		Drug Info		Anti-inhibitor coagulant complex		Drug Info
Drug Type		Small molecule				Protein/peptide
Therapeutic Class		Antifibrinolytic Agents				Coagulation Modifiers

Mechanism of Tranexamic acid-Anti-inhibitor coagulant complex Interaction (Severity Level: Major)
Additive thrombogenic effects Click to Show/Hide Mechanism Graph
Drug Name		Tranexamic acid				Anti-inhibitor coagulant complex
Mechanism		Thrombogenic effects				Thrombogenic effects
Key Mechanism Factor 1
		Factor Name		Thrombogenic effects
		Factor Description		Drug-induced thrombosis disrupts the balance between thrombogenic factors and protective mechanisms and tends to produce thrombosis. Drug-induced thrombosis usually causes venous thrombotic events, and arterial thrombotic events are also noted as a result of drug administration
Mechanism Description		Additive thrombogenic effects by the combination of Tranexamic acid and Anti-inhibitor coagulant complex

Recommended Action
Management		Concomitant administration of antifibrinolytic agents with other hemostatic agents should generally be avoided. Consult the manufacturer's product labeling for recommended dosing intervals between products.

References
1	Product Information. LYSTEDA (tranexamic acid). Xanodyne Pharmaceuticals Inc, Newport, KY.
2	Product Information. Cyklokapron (tranexamic acid). Pharmacia and Upjohn, Kalamazoo, MI.
3	Product Information. Amicar (aminocaproic acid). Immunex Corporation, Seattle, WA.